Brucellosis Vaccines Market Size, Share & Trends Analysis Report By Product (S19 vaccine and RB51 vaccine strain), By Applications (Farm, Laboratory), By End Use, By Region, and Segment Forecasts - 2035

Brucellosis Vaccines Market Overview

brucellosis vaccines market size was valued at USD 11.83 million in 2025 and is poised to grow from USD 12.27 million in 2026 to USD 13.69 million by 2035, growing at a CAGR of 3.7% during the forecast period (2026-2035).

The brucellosis vaccines market is being shaped by government-led livestock immunization, expanding disease surveillance, One Health programs, improved cold-chain infrastructure, and stronger attention to reproductive disease prevention in cattle and buffalo populations. S19 vaccine continues to represent the larger product category, accounting for approximately 64% of current market demand, while RB51 vaccine strain represents nearly 36%. Farm applications dominate with approximately 91% share because vaccination is primarily conducted through field-based animal health programs, organized dairy farms, cattle operations, and government vaccination campaigns. Laboratory applications represent approximately 9% and remain important for vaccine evaluation, quality testing, research, strain characterization, and diagnostic studies. Global vaccination coverage among cattle populations at risk of Brucella abortus was estimated at only about 7.46% in 2025, demonstrating substantial remaining scope for vaccination programs in endemic territories. The strongest demand continues to originate from regions with large cattle populations and persistent brucellosis exposure, particularly Asia-Pacific, Latin America, the Middle East, and parts of Africa.

The United States represents a specialized brucellosis vaccine environment because bovine brucellosis has been largely eliminated from commercial livestock populations, while wildlife reservoirs remain relevant around the Greater Yellowstone Area. RB51 vaccine strain has been used in U.S. cattle programs since 1996 and is currently licensed for non-pregnant female cattle between 4 and 12 months of age. Approximately 3.5 million calves are vaccinated annually as part of continuing disease-prevention efforts, supporting stable demand for veterinary vaccination and surveillance capabilities. The U.S. market differs from many endemic economies because purchasing is driven more by disease-freedom maintenance, targeted risk management, veterinary oversight, and wildlife-livestock interface control than by nationwide emergency vaccination.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: S19 vaccine is expected to remain the leading product type with approximately 64% market share, supported by established calfhood immunization programs, long-term field experience, government procurement, and extensive use across endemic cattle populations.
• Leading Application: Farm applications are projected to account for approximately 91% of market demand because brucellosis control primarily depends on field vaccination of eligible livestock through dairy farms, cattle holdings, veterinary campaigns, and organized disease-control programs.
• Leading Region: Asia-Pacific is expected to lead with approximately 42% market share, supported by large cattle and buffalo populations, endemic disease conditions, expanding veterinary infrastructure, and government-funded vaccination programs across major livestock-producing economies.
• Fastest Growing Region: Asia-Pacific is projected to record the fastest expansion at approximately 4.6% annually as governments strengthen calfhood vaccination, disease surveillance, digital livestock identification, veterinary service delivery, and coordinated zoonotic disease prevention.
• Technology Trend: Differentiation-compatible vaccination is gaining importance, with RB51 vaccine strain representing approximately 36% of demand as veterinary authorities increasingly prioritize immunization approaches that minimize interference with conventional serological surveillance programs.
• Market Driver: Government vaccination campaigns remain the strongest growth driver, illustrated by India administering approximately 43.9 million cumulative brucellosis vaccinations by January 2025 under nationally coordinated livestock disease-control initiatives.
• Competitive Landscape: Competition is increasingly influenced by manufacturing capacity and public procurement, while the 2 leading identified suppliers collectively represent approximately 27% of the competitive market, leaving substantial participation for regional veterinary vaccine manufacturers.
• Future Outlook: Vaccination coverage presents considerable expansion potential because only approximately 7.5 cattle out of every 100 considered at risk globally received Brucella abortus vaccination during 2025, reinforcing the long-term need for scalable preventive programs.

Latest Trends

Large-scale preventive vaccination is increasingly being integrated with surveillance, animal identification, epidemiological monitoring, and centralized procurement. Government veterinary authorities are moving away from isolated vaccination events toward structured programs covering eligible animal cohorts through defined operational cycles. India illustrates this transition, with cumulative brucellosis vaccination reaching approximately 43.9 million animals by January 2025. Updated operational frameworks introduced during 2026 emphasize planned vaccination cycles, cold-chain assessment, workforce training, microplanning, deworming, awareness programs, and post-vaccination monitoring. Eligible female bovine calves are typically targeted during a defined early-life age window, enabling vaccination to provide long-term protection while reducing unnecessary repeat administration. The reduction of reported brucellosis outbreaks in India from 22 during 2019 to 6 during 2025 demonstrates how sustained vaccination and surveillance can influence disease-control outcomes.

Another important trend is the increasing use of vaccine strategies compatible with diagnostic surveillance. RB51 vaccine strain is particularly relevant because vaccination produces an antibody response distinguishable from conventional responses associated with natural infection, supporting disease-monitoring programs where serological differentiation is operationally important. In the United States, approximately 3.5 million calves continue to receive brucellosis vaccination annually despite the disease having been largely removed from commercial cattle populations. Research is also examining vaccination schedules in adult cattle populations where brucellosis remains endemic. Field investigations involving herds with approximately 6% to 8% seropositive prevalence have evaluated different RB51 vaccination approaches, demonstrating continued technical interest in optimizing protection.

Market Dynamics

Driver

""Government-backed livestock immunization is accelerating preventive brucellosis control.""

National disease-control programs are the principal structural driver for brucellosis vaccine demand because bovine vaccination is frequently coordinated through government veterinary agencies rather than individual animal owners. India represents one of the clearest examples, with approximately 43.9 million cumulative brucellosis vaccinations completed by January 2025. The national strategy targets eligible female bovine calves, generally during the 4 to 8 month age period, using once-in-a-lifetime vaccination as a major preventive measure. Such programs create predictable requirements for vaccine production, freeze-dried formulations, sterile diluent, syringes, cold-chain transportation, trained vaccinators, animal identification, and post-vaccination reporting. The reduction in India's reported brucellosis outbreaks from 22 cases in 2019 to 6 outbreaks during 2025 provides measurable evidence that coordinated vaccination and surveillance can contribute to disease reduction over multiple years.

The public-health dimension provides an additional driver because brucellosis is a zoonotic infection affecting both animals and humans. Cattle, sheep, goats, swine, and several other animal species can carry Brucella organisms, while occupational exposure creates risks for farmers, veterinarians, laboratory personnel, slaughterhouse workers, and others handling infected reproductive material. Global estimates indicate that vaccination coverage against Brucella abortus among cattle populations considered at risk was approximately 7.46% in 2025, substantially below the coverage levels required for comprehensive control in many endemic environments. With Farm applications accounting for approximately 91% of demand, field vaccination remains the central commercial pathway for manufacturers.

Restraint

""Live vaccine handling and operational limitations constrain wider vaccination coverage.""

Brucellosis vaccination requires carefully controlled administration because S19 vaccine and RB51 vaccine strain are live attenuated biological products. This creates more demanding handling requirements than conventional non-live veterinary products. Vaccinators must follow appropriate biosafety procedures, maintain cold-chain integrity, use correct reconstitution methods, administer appropriate doses, and prevent accidental human exposure. In current Indian procurement specifications, reconstituted S19 vaccine doses can require at least 4 billion colony-forming units of live Brucella abortus organisms in a 2 ml dose. Maintaining biological potency across production, distribution, storage, field reconstitution, and administration creates operational complexity, particularly in remote livestock areas where refrigeration and veterinary staffing may be inconsistent.

Another restraint is the substantial difference in vaccination requirements between endemic and disease-free territories. Several developed livestock markets have eliminated or substantially controlled bovine brucellosis, reducing the need for broad routine vaccination. The United States still vaccinates approximately 3.5 million calves annually, but disease risk is geographically concentrated and differs significantly from conditions in high-prevalence economies. Countries approaching eradication may progressively shift from mass vaccination toward surveillance, individual animal testing, movement control, and removal of infected animals. Global cattle vaccination coverage against Brucella abortus was approximately 7.46% during 2025, but this relatively low figure reflects major epidemiological differences among countries rather than a universally addressable population.

Opportunity

""Low vaccination penetration creates significant expansion potential in endemic livestock regions.""

The large difference between at-risk cattle populations and currently vaccinated animals represents the most significant long-term market opportunity. Approximately 7.46% of cattle populations considered at risk globally were covered by Brucella abortus vaccination during 2025, leaving more than 90% outside reported vaccination coverage. Not every unvaccinated animal requires vaccination because disease-control strategies vary by epidemiological status, age, sex, country, and herd conditions, but the figure demonstrates substantial room for program expansion. Asia-Pacific alone is estimated to represent approximately 42% of current brucellosis vaccine demand, supported by extensive cattle and buffalo populations and government programs. Manufacturers capable of supplying reliable large-volume freeze-dried vaccines can benefit from procurement programs covering millions of eligible calves annually.

Integration of vaccination with digital animal health infrastructure provides another opportunity. Modern disease-control programs increasingly use electronic animal identification, mobile vaccination records, geotagged field reporting, batch tracking, cold-chain monitoring, and centralized epidemiological databases. A structured vaccination campaign can include multiple operational milestones over approximately 120 days, ranging from target finalization and cold-chain assessment to workforce training, vaccination implementation, and reporting. Laboratory applications, although representing only approximately 9% of market demand, also offer opportunities for challenge studies, vaccine quality evaluation, epidemiological research, potency assessment, and improved diagnostic differentiation.

Challenge

""Achieving consistent last-mile coverage remains difficult across fragmented livestock systems.""

Brucellosis vaccination programs frequently operate across millions of small farms, creating logistical challenges in identifying eligible animals and delivering vaccines within the recommended age window. India alone has vaccinated approximately 43.9 million animals cumulatively under its brucellosis program, illustrating the operational scale required for nationwide implementation. Veterinary departments must coordinate vaccine procurement, distribution, refrigeration, vaccinators, animal owners, identification, awareness, adverse-event reporting, and data entry. Female calves may become eligible continuously rather than at a single point during the year, requiring repeated operational cycles and updated livestock records.

Disease surveillance creates another challenge because vaccination alone cannot eliminate brucellosis from all livestock systems. As prevalence declines, veterinary authorities increasingly need serological screening, confirmatory laboratory testing, movement control, biosecurity, herd-level investigation, and removal of infected animals. Field research in endemic Brazilian beef farms has examined populations with approximately 6% to 8% seropositive cows, illustrating how infection can remain established even where calfhood vaccination has previously occurred. Achieving eradication can require several years of sustained vaccination followed by increasingly intensive surveillance.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

S19 vaccine: S19 vaccine represents approximately 64% of the brucellosis vaccines market and remains the leading product type because of its long history in bovine brucellosis control, established manufacturing procedures, government acceptance, and widespread use for calfhood vaccination. In India, current programs target female cattle and buffalo calves generally between 4 and 8 months of age, supporting recurring annual demand as new animals enter the eligible cohort. Procurement specifications for freeze-dried S19 vaccine can require each reconstituted 2 ml dose to contain at least 4 billion colony-forming units of live organisms.

RB51 vaccine strain: RB51 vaccine strain accounts for approximately 36% of market demand and has an important position in countries prioritizing compatibility between vaccination and serological surveillance. The vaccine has been licensed for cattle use in the United States since 1996 and is used in non-pregnant female cattle, with approximately 3.5 million calves vaccinated annually in continuing disease-control programs. The segment is expected to gain strategic importance as more veterinary programs move from broad disease suppression toward targeted vaccination combined with surveillance and epidemiological monitoring.

By Applications

Farm: Farm applications account for approximately 91% of the brucellosis vaccines market and represent the primary channel through which vaccination reaches cattle populations. Government veterinary departments, dairy farms, cattle ranches, cooperatives, livestock owners, and field veterinarians conduct immunization as part of herd health and national disease-control programs. India's cumulative administration of approximately 43.9 million brucellosis vaccinations by January 2025 demonstrates the scale achievable through organized field programs.

Laboratory: Laboratory applications represent approximately 9% of market demand and cover vaccine research, quality control, potency testing, strain characterization, diagnostic development, epidemiological studies, and controlled vaccine-effectiveness investigations. Recent systematic evaluations of S19 vaccine and RB51 vaccine strain have examined dozens of field trials, including 33 identified trial comparisons across selected evidence bases. Although considerably smaller than Farm applications, the Laboratory segment has strategic importance because improved diagnostic accuracy and vaccine quality testing directly influence large-scale disease-control campaigns.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America accounts for approximately 18% of the brucellosis vaccines market and represents a mature disease-control environment characterized by strong veterinary surveillance and targeted vaccination. The United States eliminated bovine brucellosis from most commercial cattle populations following decades of coordinated federal and state intervention. Remaining epidemiological concern is concentrated around wildlife reservoirs in the Greater Yellowstone Area, requiring targeted risk management rather than universal nationwide immunization.

Approximately 3.5 million calves continue to receive brucellosis vaccination annually in the United States, sustaining demand for RB51 vaccine strain and veterinary administration services. RB51 has been licensed for cattle vaccination since 1996 and is particularly suitable for surveillance-oriented programs because conventional serological testing can more effectively distinguish vaccination from natural infection. North America's future demand is expected to remain comparatively stable as disease-freedom maintenance, wildlife-livestock interfaces, animal movement controls, and targeted vaccination replace broad emergency immunization.

Europe

Europe represents approximately 15% of market demand, although vaccination requirements vary substantially between western, northern, Mediterranean, and neighboring livestock regions. Several Western and Northern European countries have achieved official freedom or very low prevalence, reducing the need for routine vaccination and shifting expenditure toward surveillance and outbreak response. Mediterranean livestock systems face comparatively greater historical exposure, creating continued requirements for veterinary preparedness and diagnostic capacity.

European veterinary policy increasingly emphasizes surveillance, traceability, animal movement controls, laboratory confirmation, and rapid containment. In low-prevalence environments, vaccination may be replaced by test-and-removal strategies once infection falls below practical eradication thresholds. European manufacturers operate within a highly regulated environment where product consistency, pharmacovigilance, manufacturing quality, and biosafety influence procurement decisions.

Asia-Pacific

Asia-Pacific leads the brucellosis vaccines market with approximately 42% share because of its large cattle and buffalo populations, endemic disease burden, expanding dairy industry, and government-supported immunization programs. India and China are particularly important markets because both countries maintain extensive livestock populations and veterinary disease-control infrastructure. India alone had administered approximately 43.9 million cumulative brucellosis vaccinations by January 2025 under coordinated livestock vaccination initiatives.

The region is also expected to achieve the fastest growth, with demand expanding at approximately 4.6% annually as governments strengthen veterinary infrastructure, surveillance, vaccine procurement, and animal identification. India's reported brucellosis outbreaks declined from 22 during 2019 to 6 during 2025, reinforcing policy support for sustained disease-control interventions. Regional manufacturers strengthen local supply capabilities and can support procurement programs requiring millions of doses.

Middle East & Africa

The Middle East & Africa collectively represent approximately 8% of current market demand but provide considerable long-term vaccination potential because brucellosis remains endemic across numerous livestock-producing territories. Disease incidence is particularly relevant in parts of the Middle East and sub-Saharan Africa, where cattle, sheep, goats, and mixed livestock systems contribute directly to rural livelihoods and household food production.

Vaccination coverage remains uneven across more than 50 African countries and multiple Middle Eastern livestock systems because veterinary infrastructure, laboratory availability, cold-chain capacity, farmer awareness, and public funding vary considerably. Regional growth is expected to exceed approximately 4% annually in expanding vaccination territories as One Health strategies increasingly connect livestock disease prevention with human health, food safety, dairy production, and agricultural development.

List of Top Brucellosis Vaccines Companies

• Boehringer Ingelheim (Germany)
• Biogénesis Bagó (Argentina)
• CZ Veterinaria (Spain)
• Indian Immunologicals Limited (India)
• Qilu Animal Health Products Co., Ltd. (China)
• Tecnovax (Argentina)
• Hester Biosciences (India)
• Zoetis (U.S.)
• Ceva Santé Animale (France)
• Biovet (Spain)

Top 2 Companies Market Share

Boehringer Ingelheim: Boehringer Ingelheim is estimated to account for approximately 15% of the identified competitive market, supported by its extensive animal-health capabilities, international distribution network, veterinary biological expertise, and presence across major livestock-producing economies. The company's competitive position benefits from operations spanning more than 100 international markets and a broad veterinary health infrastructure capable of supporting regulated biological products.

Biogénesis Bagó: Biogénesis Bagó is estimated to represent approximately 12% of the identified competitive market and maintains a strong position through its Latin American animal-health specialization, biological manufacturing capabilities, and exposure to cattle-intensive agricultural markets. Together, the 2 leading identified companies account for approximately 27% of competitive participation, indicating that the brucellosis vaccine sector remains distributed among multinational and regional manufacturers.

Investment Analysis

Investment in the brucellosis vaccines market is increasingly focused on manufacturing capacity, freeze-drying technology, biosafety, quality control, cold-chain resilience, and government procurement readiness. Global cattle vaccination coverage against Brucella abortus remained approximately 7.46% among populations considered at risk during 2025, indicating significant potential for additional immunization where epidemiologically appropriate. Manufacturers serving large national programs require facilities capable of producing millions of consistent live attenuated doses while maintaining organism concentration, sterility, stability, and regulatory compliance. Investment opportunities are especially significant in Asia-Pacific, which accounts for approximately 42% of current market demand.

Digital vaccination infrastructure represents another attractive investment area. Government programs increasingly require traceable vaccine batches, animal identification, cold-chain monitoring, field-worker applications, geotagged administration, and centralized coverage dashboards. Operational vaccination cycles can extend approximately 120 days and require coordination among procurement authorities, veterinary officers, vaccinators, laboratories, farmers, and logistics providers. Laboratory infrastructure is also important despite accounting for approximately 9% of application demand because surveillance, serological testing, potency evaluation, and outbreak confirmation determine when vaccination programs should expand, contract, or transition toward test-and-removal strategies.

New Product Development

New product development in brucellosis vaccination is concentrating on improved safety, diagnostic compatibility, biological stability, convenient field administration, and optimized immunization strategies. RB51 vaccine strain, representing approximately 36% of current product demand, demonstrates the importance of vaccines that minimize interference with conventional serological surveillance. Research continues to examine whether alternative schedules, including 1-dose and 2-dose approaches in selected adult cattle populations, can improve disease control under endemic conditions. Product developers are also focusing on freeze-dried stability, standardized viable organism concentrations, simplified reconstitution, smaller multidose presentations, and improved packaging.

S19 vaccine development remains relevant because the product holds approximately 64% market share and continues to support major government vaccination programs. Current specifications in large procurement environments can require a 2 ml reconstituted dose containing at least 4 billion viable organisms, creating stringent manufacturing and quality-control requirements. Future innovation is likely to concentrate on production consistency, thermal stability, safer administration systems, traceable packaging, and integration with digital vaccination records.

Five Recent Developments

• January 2024: Veterinary vaccine programs increased emphasis on integrated brucellosis surveillance and field vaccination during 2024 as endemic cattle-producing countries strengthened reproductive disease management, with several control programs targeting female calves within approximately 4 to 8 months of age for preventive immunization.
• November 2024: Field evidence assessing S19 vaccine and RB51 vaccine strain was consolidated through systematic evaluation of 17 selected studies containing 33 vaccine trials, strengthening the technical evidence base used by veterinary authorities when designing bovine brucellosis vaccination and surveillance strategies.
• February 2025: National vaccination reporting in India showed cumulative administration of approximately 43.9 million brucellosis vaccinations by January 2025, demonstrating the scale of government-supported livestock immunization and reinforcing procurement requirements for manufacturers capable of supplying large quantities of S19 vaccine.
• May 2025: Global animal-health assessment placed vaccination among the major tools for controlling priority livestock diseases during 2025, while estimated Brucella abortus vaccination coverage remained approximately 7.46% among cattle populations considered at risk, highlighting substantial geographic gaps in preventive coverage.
• February 2026: Updated brucellosis vaccination operating procedures introduced a structured approximately 120-day field implementation cycle covering target finalization, cold-chain assessment, workforce preparation, microplanning, eligible animal vaccination, and monitoring, strengthening standardization across large-scale livestock disease-control campaigns.

Report Coverage

The brucellosis vaccines market assessment covers industry conditions from the 2025 base period through the 2026-2035 forecast horizon and evaluates product adoption, application structure, regional demand, competitive positioning, government vaccination programs, veterinary infrastructure, disease surveillance, and technological development. The product segmentation is limited to the 2 specified categories, S19 vaccine and RB51 vaccine strain, with estimated shares of approximately 64% and 36%, respectively. Application analysis covers Farm and Laboratory settings, representing approximately 91% and 9% of market demand. Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with Asia-Pacific holding approximately 42% of current demand.

The competitive assessment covers 10 specified companies: Boehringer Ingelheim, Biogénesis Bagó, CZ Veterinaria, Indian Immunologicals Limited, Qilu Animal Health Products Co., Ltd., Tecnovax, Hester Biosciences, Zoetis, Ceva Santé Animale, and Biovet. The analysis evaluates manufacturing capacity, geographic positioning, government procurement participation, biological production capabilities, cold-chain requirements, product differentiation, and veterinary distribution. Current market conditions are influenced by global cattle vaccination coverage of approximately 7.46% among at-risk populations, India's cumulative administration of approximately 43.9 million brucellosis vaccinations by January 2025, and continued U.S. vaccination of approximately 3.5 million calves annually.